OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
048870$2020.0057

Synergy Innovation Co Ltd

Medical Equipment, Supplies & DistributionVerified

The company's capital structure is characterized by a low debt-to-equity ratio of 0.17, indicating a conservative leverage profile. Its liquidity position is moderate, with a current ratio of 3.56, suggesting the company can cover short-term obligations with a reasonable buffer. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. The price-to-book ratio of 0.84 implies that the company's market value is below its book value, which may reflect market skepticism about its asset quality or future earnings potential. Profitability metrics show a return on equity (ROE) of 1.42% and a return on assets (ROA) of 0.89%, both of which are below the typical thresholds for high-performing firms in the semiconductor industry. The company's gross profit margin is 44.5%, calculated from a gross profit of KRW 50.34 billion on revenue of KRW 113.05 billion, but its operating margin is only 16.8%, indicating significant operating expenses relative to revenue. These figures suggest that while the company is generating revenue, it is not efficiently converting it into operating profits. The company's revenue is concentrated in a few key segments, with the majority derived from the production of camera application processors and multimedia application processors. Geographically, the company's exposure is primarily to the Korean market, with limited diversification into other regions. This concentration increases vulnerability to regional economic downturns or shifts in demand. Looking ahead, the company's growth trajectory appears modest. The outlook for the current fiscal year (FY) shows a projected revenue increase of 2.3%, with a further 1.8% growth expected in the following FY. These figures are below the industry median for growth expectations, suggesting that the company may struggle to outperform its peers in terms of revenue expansion. The company's capital expenditure of KRW 5.37 billion is relatively low, indicating a cautious approach to investment in new capacity or technology. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low dilution risk is supported by a stable share count, with no significant changes in shares outstanding between basic and diluted figures. However, the risk of dilution could increase if the company issues new shares to fund operations or strategic initiatives. The risk assessment also notes that the company's net cash position is negative after accounting for total debt, which could limit its ability to invest in growth opportunities or withstand a downturn. Recent events, including quarterly earnings reports and management commentary, indicate a focus on cost control and operational efficiency. The company has not disclosed any major new product launches or strategic acquisitions in the latest filings. Management has emphasized the need to maintain a strong balance sheet and improve profitability through process optimization.

30-day price · 048870-247.00 (-11.3%)
Low$1900.00High$2205.00Close$1938.00As of12 May, 00:00 UTC
Profile
CompanySynergy Innovation Co Ltd
Ticker048870.KQ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Synergy Innovation Co., Ltd. designs and manufactures semiconductor products, including camera application processors (CAPs), application processors (APs), multimedia application processors (MAPs), and image signal processors (ISPs), primarily for use in mobile phone cameras and multimedia products.

Classification. The company is classified under the industry "Medical Equipment, Supplies & Distribution" within the "Healthcare Services & Equipment" business sector, with a confidence level of 0.92.

The company's capital structure is characterized by a low debt-to-equity ratio of 0.17, indicating a conservative leverage profile. Its liquidity position is moderate, with a current ratio of 3.56, suggesting the company can cover short-term obligations with a reasonable buffer. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. The price-to-book ratio of 0.84 implies that the company's market value is below its book value, which may reflect market skepticism about its asset quality or future earnings potential. Profitability metrics show a return on equity (ROE) of 1.42% and a return on assets (ROA) of 0.89%, both of which are below the typical thresholds for high-performing firms in the semiconductor industry. The company's gross profit margin is 44.5%, calculated from a gross profit of KRW 50.34 billion on revenue of KRW 113.05 billion, but its operating margin is only 16.8%, indicating significant operating expenses relative to revenue. These figures suggest that while the company is generating revenue, it is not efficiently converting it into operating profits. The company's revenue is concentrated in a few key segments, with the majority derived from the production of camera application processors and multimedia application processors. Geographically, the company's exposure is primarily to the Korean market, with limited diversification into other regions. This concentration increases vulnerability to regional economic downturns or shifts in demand. Looking ahead, the company's growth trajectory appears modest. The outlook for the current fiscal year (FY) shows a projected revenue increase of 2.3%, with a further 1.8% growth expected in the following FY. These figures are below the industry median for growth expectations, suggesting that the company may struggle to outperform its peers in terms of revenue expansion. The company's capital expenditure of KRW 5.37 billion is relatively low, indicating a cautious approach to investment in new capacity or technology. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low dilution risk is supported by a stable share count, with no significant changes in shares outstanding between basic and diluted figures. However, the risk of dilution could increase if the company issues new shares to fund operations or strategic initiatives. The risk assessment also notes that the company's net cash position is negative after accounting for total debt, which could limit its ability to invest in growth opportunities or withstand a downturn. Recent events, including quarterly earnings reports and management commentary, indicate a focus on cost control and operational efficiency. The company has not disclosed any major new product launches or strategic acquisitions in the latest filings. Management has emphasized the need to maintain a strong balance sheet and improve profitability through process optimization.
Key takeaways
  • The company maintains a conservative capital structure with a low debt-to-equity ratio of 0.17.
  • Profitability is weak, with ROE and ROA below industry norms.
  • Revenue is concentrated in a few product lines and geographic regions, increasing exposure to market volatility.
  • Growth expectations are modest, with revenue growth projected at 2.3% for the current FY and 1.8% for the next.
  • Liquidity risk is moderate, and dilution risk is low, but the company's net cash position is negative after debt.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$113.05B
Gross profit$50.34B
Operating income$19.03B
Net income$3.01B
R&D
SG&A
D&A
SBC
Operating cash flow$14.78B
CapEx-$5.37B
Free cash flow$9.66B
Total assets$336.89B
Total liabilities$125.37B
Total equity$211.51B
Cash & equivalents
Long-term debt$35.90B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$2020.00
Market cap$177.98B
Enterprise value$213.87B
P/E59.1
Reported non-GAAP P/E
EV/Revenue1.9
EV/Op income11.2
EV/OCF14.5
P/B0.8
P/Tangible book0.8
Tangible book$211.51B
Net cash-$35.90B
Current ratio3.6
Debt/Equity0.2
ROA0.9%
ROE1.4%
Cash conversion4.9%
CapEx/Revenue-4.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric048870Activity
Op margin16.8%13.3% medp25 5.9% · p75 13.5%top quartile
Net margin2.7%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin44.5%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-4.8%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity17.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 14:08 UTC#28a76aab
Market quoteclose KRW 2020.00 · shares 0.09B diluted
no public URL
2026-05-10 14:08 UTC#530dc29e
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 14:10 UTCJob: a709e0f0